BPC-157
Staresinic and colleagues, 2003, rat tendon experiment studied healing after the Achilles tendon was cut. Mechanical, functional, and tissue outcomes help explain the repair interest. The work does not establish a human tendon treatment.
Hsieh and colleagues, 2017, vascular signaling experiments examined VEGFR2-related activity using cells and animal models. The paper supplies a possible mechanism involving blood-vessel growth, rather than a clinical recovery result.
Xue and colleagues, 2004, rat gastric-ulcer experiments investigated stomach-lining injury. Its relevance is to the experimental gut model; it does not establish treatment for a person's digestive symptoms.
Lee and Burgess, 2025, intravenous safety pilot reported short-term observations in two healthy adults. It is cited for what was monitored and the limits of a very small safety report, not for injury healing.
McGuire and colleagues, 2025, musculoskeletal narrative review places the animal findings beside the limited human record. A review provides context without adding a controlled clinical trial of its own.
FDA, 2026, assessment of BPC-157 examines identity, human and animal evidence, and safety questions for the compounding review. It provides official context for limitations that a short study summary can overlook.
TB-500 and thymosin beta-4
Irobi and colleagues, 2004, actin structural work investigated the interaction between actin and a thymosin-beta-4-containing construct. It helps explain cell-movement interest without demonstrating a treatment effect in people.
Malinda and colleagues, 1999, rat wound experiments tested full-length thymosin beta-4. The distinction from the TB-500 fragment remains essential when interpreting the reported repair measurements.
Goldstein and colleagues, 2012, review of the full protein discusses actin handling and repair-related biology. The review concerns thymosin beta-4 and cannot establish identical behavior for its capped fragment.
Ruff and colleagues, 2010, early volunteer safety study examined intravenous full-length thymosin beta-4 in forty healthy volunteers. It supplies no direct safety finding for the shorter TB-500 fragment.
FDA, 2026, assessment of TB-500-related substances distinguishes the fragment from the longer protein and examines the available literature. Its search findings belong to the document's date and scope.
GHK, GHK-Cu, and KPV
Pickart and colleagues, 2015, skin-biology review brings together laboratory findings and small topical reports involving GHK and copper peptides. The strength and availability of the underlying human reports remain important limitations.
Pickart and Margolina, 2018, review of gene-related findings discusses cell and gene-expression work. It does not demonstrate reversal of a person's biological age or establish a systemic treatment benefit.
Mortazavi and colleagues, 2025, topical-delivery review examines GHK formulations, skin penetration, and limited clinical evidence. It is useful for understanding why activity in a laboratory does not settle delivery through intact skin.
Hostynek and colleagues, 2011, removed-skin experiment measured copper passage and retention after application of a tripeptide complex. This was a laboratory skin model, not a trial of cosmetic outcomes in participants.
Lee and colleagues, 2016, combination hair study tested GHK without copper alongside another active ingredient in forty-five men. The mixture prevents assigning the reported hair-count difference to GHK-Cu alone.
Dalmasso and colleagues, 2008, intestinal KPV experiments investigated uptake and inflammation-related activity in cells and mice. It supports discussion of an ingredient rationale, not a human benefit from KLOW.
Wider safety and regulatory context
Mendias and Awan, 2026, sports-medicine review examines approved and unapproved peptide therapies. It frames the shortage of rigorous human safety evidence beside encouraging preclinical repair findings.
FDA safety-risk and withdrawn-nomination tables, content current as of April 22, 2026, distinguish the listed groups and retain substance-specific concerns. Withdrawal is not clearance or approval for compounding.
FDA explanation of compounded-drug risks describes the absence of FDA premarket approval for compounded medicines. A prescription and an approved drug are not interchangeable regulatory facts.
FDA explanation of cosmetic oversight describes how cosmetics are regulated without ordinary premarket approval. This context helps keep topical skin-care products separate from claims about injected medicines.